The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathological features of program death ligand-1 (PD-L1) expression with tumor-infiltrating lymphocytes (TILs), mismatch repair (MMR) and Epstein-Barr virus (EBV) status in a large cohort of gastric cancer.
 
Akihito Kawazoe
No Relationships to Disclose
 
Takeshi Kuwata
No Relationships to Disclose
 
Yasutoshi Kuboki
No Relationships to Disclose
 
Kohei Shitara
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Novartis; Sanofi; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Bayer; Chugai Pharma; Lilly; Takeda
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); MSD (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Akiko Nagatsuma
No Relationships to Disclose
 
Takayuki Yoshino
Research Funding - Dainippon Sumitomo Pharma
 
Toshihiko Doi
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Nippon Boehringer Ingelheim; Novartis; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Atsushi Ohtsu
Employment - Celgene (I)
Research Funding - Bristol-Myers Squibb
 
Atsushi Ochiai
Research Funding - Amgen; Bayer; Eisai; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Ventana Medical Systems